ORLANDO -- Researchers identified four predictors of clinically relevant bleeding in patients receiving extended anticoagulation with apixaban (Eliquis) for cancer-associated venous thromboembolism ...
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...